Contineum Therapeutics, Inc.
NASDAQContineum Therapeutics reports after the close today with short sellers having doubled their exposure over the past month while options traders stack puts at a ratio well above recent norms — making this one of the more charged setups in small-cap biotech ahead of the print. The clearest tension sits in the short interest data. Bears have been aggressive: short interest climbed 75%…
CTNM short interest plummets 48.6% in one week to 6.95% of float, lowest level since early May.
Snapshot as of 8 Aug 2026
Contineum Therapeutics reports after the close today with short sellers having doubled their exposure over the past month while options traders stack puts at a ratio well above recent norms — making this one of the…
Contineum Therapeutics heads into its May 7 Q1 2026 results with short sellers holding a meaningful position — but options traders telling a noticeably different story. Short interest is a genuine factor here. At 13.5%…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CTNM — free to start on ORTEX.
Sign up for free →Open CTNM on ORTEX